Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.
Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.
复制标题
轻度SARS-COV-2感染后一年，长期的共同结果：全国队列研究。
DOI：
10.1136/bmj-2022-072529
复制
发表时间：
2023-01-11
影响因子：
105.7
通讯作者：
Greenfeld, Shira
中科院分区：
文献类型：
--
作者：
Mizrahi, Barak;Sudry, Tamar;Flaks-Manov, Natalie;Yehezkelli, Yoav;Kalkstein, Nir;Akiva, Pinchas;Ekka-Zohar, Anat;Ben David, Shirley Shapiro;Lerner, Uri;Bivas-Benita, Maytal;Greenfeld, Shira
确定轻度疾病患者感染后一年内长期COVID的临床后遗症，并评估其与年龄、性别、SARS-CoV-2变异株和疫苗接种状况的相关性。回顾性全国队列研究。来自以色列全国性医疗保健组织的电子病历。1 913 234名Maccabi Healthcare Services所有年龄段的成员，他们在2020年3月1日至2021年10月1日期间进行了SARS-CoV-2的聚合酶链反应测试。一份基于证据的列表，列出了70例报告的SARS-CoV-2感染患者与未感染者相匹配的长期COVID结局的风险，调整了年龄和性别，并按SARS-CoV-2变异体分层，以及SARS-CoV-2突破性感染患者与未接种疫苗的感染对照组相比的风险。使用感染后早期（30 - 180天）和晚期（180 - 360天）期间测量的每10000例患者的风险比和风险差异来比较风险。COVID-19感染与嗅觉丧失和味觉障碍的早期和晚期风险增加显著相关（风险比4.59（95%置信区间3.63至5.80），风险差19.6（95%置信区间16.9 - 22.4）早期; 2.96（2.29至3.82）、11.0（晚期8.5 - 13.6），认知障碍（1.85（1.58至2.17），12.8，（9.6至16.1）; 1.69（1.45至1.96），13.3（9.4 - 17.3））、呼吸困难（1.79（1.68至1.90），85.7）（76.9至94.5）; 1.30（1.22至1.38），35.4（26.3至44.6）），虚弱（1.78（1.69至1.88），108.5，98.4至118.6; 1.30（1.22至1.37），50.2（39.4至61.1））和心悸（1.49（1.35至1.64），22.1（16.8至27.4）; 1.16（1.05至1.27），8.3（2.4至14.1）），链球菌扁桃体炎和头晕的过度风险显著但较低。脱发、胸痛、咳嗽、肌痛和呼吸系统疾病仅在早期显著增加。男性和女性患者表现出微小的差异，在新冠肺炎的早期阶段，儿童的结局比成人少，大多数在晚期消退。研究结果在SARS-CoV-2变体中保持一致。与未接种疫苗的感染患者相比，接种疫苗的突破性SARS-CoV-2感染患者呼吸困难的风险较低，其他结局的风险相似。这项全国性的研究表明，轻度新冠肺炎患者面临少数健康后果的风险，其中大多数在诊断后一年内得到解决。
To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status. Retrospective nationwide cohort study. Electronic medical records from an Israeli nationwide healthcare organisation. 1 913 234 Maccabi Healthcare Services members of all ages who did a polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 1 October 2021. Risk of an evidence based list of 70 reported long covid outcomes in unvaccinated patients infected with SARS-CoV-2 matched to uninfected people, adjusted for age and sex and stratified by SARS-CoV-2 variants, and risk in patients with a breakthrough SARS-CoV-2 infection compared with unvaccinated infected controls. Risks were compared using hazard ratios and risk differences per 10 000 patients measured during the early (30-180 days) and late (180-360 days) time periods after infection. Covid-19 infection was significantly associated with increased risks in early and late periods for anosmia and dysgeusia (hazard ratio 4.59 (95% confidence interval 3.63 to 5.80), risk difference 19.6 (95% confidence interval 16.9 to 22.4) in early period; 2.96 (2.29 to 3.82), 11.0 (8.5 to 13.6) in late period), cognitive impairment (1.85 (1.58 to 2.17), 12.8, (9.6 to 16.1); 1.69 (1.45 to 1.96), 13.3 (9.4 to 17.3)), dyspnoea (1.79 (1.68 to 1.90), 85.7 (76.9 to 94.5); 1.30 (1.22 to 1.38), 35.4 (26.3 to 44.6)), weakness (1.78 (1.69 to 1.88), 108.5, 98.4 to 118.6; 1.30 (1.22 to 1.37), 50.2 (39.4 to 61.1)), and palpitations (1.49 (1.35 to 1.64), 22.1 (16.8 to 27.4); 1.16 (1.05 to 1.27), 8.3 (2.4 to 14.1)) and with significant but lower excess risk for streptococcal tonsillitis and dizziness. Hair loss, chest pain, cough, myalgia, and respiratory disorders were significantly increased only during the early phase. Male and female patients showed minor differences, and children had fewer outcomes than adults during the early phase of covid-19, which mostly resolved in the late period. Findings remained consistent across SARS-CoV-2 variants. Vaccinated patients with a breakthrough SARS-CoV-2 infection had a lower risk for dyspnoea and similar risk for other outcomes compared with unvaccinated infected patients. This nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis.
登录
查看更多内容
影响因子：
64.8
作者：
通讯作者：
--
DOI：
10.1016/j.xcrm.2022.100552
发表时间：
2022-03-15
期刊：
Cell reports. Medicine
影响因子：
--
作者：
Blomberg B;Cox RJ;Langeland N
通讯作者：
Langeland N
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
82.9
作者：
Blomberg B;Mohn KG;Brokstad KA;Zhou F;Linchausen DW;Hansen BA;Lartey S;Onyango TB;Kuwelker K;Sævik M;Bartsch H;Tøndel C;Kittang BR;Bergen COVID-19 Research Group;Cox RJ;Langeland N
通讯作者：
Langeland N
DOI：
10.1016/j.cities.2021.103526
发表时间：
2022-03
期刊：
Cities (London, England)
影响因子：
--
作者：
Hananel R;Fishman R;Malovicki-Yaffe N
通讯作者：
Malovicki-Yaffe N